BridgeBio Pharma Inc (BBIO) stock saw a modest uptick, ending the day at $28.79 which represents a slight increase of $2.13 or 7.99% from the prior close of $26.66. The stock opened at $26.96 and ...

On Friday, BridgeBio Pharma Inc (BBIO) stock saw a decline, ending the day at $27.33 which represents a decrease of $-0.16 or -0.58% from the prior close of $27.49. The stock opened at $27.84 and ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

GET MORE AI-GENERATED SIGNALS: December 02, 2024, 04:48 am ET, BY Jesse F.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

BridgeBio Pharma’s stock (BBIO) jumped over 16% after the FDA approved its cardiovascular drug, Attruby. This new treatment will compete with Pfizer’s (PFE) Vyndamax, which was extremely ...

Research analysts at HC Wainwright increased their FY2024 earnings estimates for shares of BridgeBio Pharma in a research ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Legend Biotech (LEGN – Research Report), Disc ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BridgeBio announced the FDA approval of Attruby (acoramidis) for the treatment of patients with ATTR-CM. The label looks clean and it includes all the relevant clinical data. Attruby's approval ...